June 15, 2020 / 12:28 PM / 21 days ago

BRIEF-Arch Biopartners Announces FDA Acknowledgement Of Investigational New Drug Application For Metablok

June 15 (Reuters) - Arch Biopartners Inc:

* ARCH BIOPARTNERS ANNOUNCES FDA ACKNOWLEDGEMENT OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR METABLOK (LSALT PEPTIDE)

* ARCH BIOPARTNERS - FDA ACKNOWLEDGEMENT ENABLES CO TO INITIATE PHASE II TRIAL IN U.S. TO PREVENT LUNG, KIDNEY ORGAN INJURY IN COVID-19 PATIENTS

* ARCH BIOPARTNERS - EXPECTS TO BEGIN PHASE II TRIAL TO PREVENT ACUTE LUNG, KIDNEY ORGAN IN COVID-19 PATIENTS BEFORE END OF SUMMER, 2020

* ARCH BIOPARTNERS INC - PRIMARY ENDPOINT OF PHASE II TRIAL WAS EXPANDED TO A COMPOSITE THAT INCLUDES PREVENTION OF ARDS AND AKI Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below